Cargando…

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates

Clinical management of human immunodeficiency virus type-1 (HIV-1) infection may be negatively impacted by either acquired or transmitted drug resistance. Here, we aim to extend our understanding of the impact of resistance-associated mutations (RAMs) on the susceptibility of clinical isolates to th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asante-Appiah, Ernest, Lai, Johnny, Wan, Hong, Yang, Dongmei, Martin, Elizabeth Anne, Sklar, Peter, Hazuda, Daria, Petropoulos, Christos J., Walworth, Charles, Grobler, Jay A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597775/ https://www.ncbi.nlm.nih.gov/pubmed/34570651 http://dx.doi.org/10.1128/AAC.01216-21

Ejemplares similares

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
por: Vaddady, Pavan, et al.
Publicado: (2020)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

Lausannevirus Encodes a Functional Dihydrofolate Reductase Susceptible to Proguanil
por: Mueller, L., et al.
Publicado: (2017)

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility
por: Farrukee, R., et al.
Publicado: (2018)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

Influenza A(H7N9) Virus Acquires Resistance-Related Neuraminidase I222T Substitution When Infected Mallards Are Exposed to Low Levels of Oseltamivir in Water
por: Gillman, Anna, et al.
Publicado: (2015)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus
por: Levendosky, Keith, et al.
Publicado: (2015)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
por: Ulferts, Rachel, et al.
Publicado: (2016)

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
por: Jean-Pierre, Ninochka, et al.
Publicado: (2016)

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
por: Krishnan, Preethi, et al.
Publicado: (2016)

Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
por: Feng, Joy Y., et al.
Publicado: (2016)

Geneticin Stabilizes the Open Conformation of the 5′ Region of Hepatitis C Virus RNA and Inhibits Viral Replication
por: Ariza-Mateos, Ascensión, et al.
Publicado: (2016)

A Continuous Enzyme-Coupled Assay for Triphosphohydrolase Activity of HIV-1 Restriction Factor SAMHD1
por: Arnold, Laurence H., et al.
Publicado: (2014)

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir
por: Schnell, Gretja, et al.
Publicado: (2015)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015)

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016)

Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture System
por: Dinkel, Kelcey D., et al.
Publicado: (2016)

PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally
por: Graci, Jason D., et al.
Publicado: (2016)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle
por: Medigeshi, Guruprasad R., et al.
Publicado: (2016)

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody
por: Meng, Weixu, et al.
Publicado: (2017)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity
por: Nevers, Quentin, et al.
Publicado: (2018)

Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment
por: Feng, Joy Y., et al.
Publicado: (2018)

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
por: Vigil, Adam, et al.
Publicado: (2018)

The Amphibian Antimicrobial Peptide Temporin B Inhibits In Vitro Herpes Simplex Virus 1 Infection
por: Marcocci, M. E., et al.
Publicado: (2018)

Selection and Characterization of Rupintrivir-Resistant Norwalk Virus Replicon Cells In Vitro
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System
por: Moure, Ricardo, et al.
Publicado: (2018)

Simple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5′-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase
por: Lu, Gaofei, et al.
Publicado: (2018)

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
por: Krishnan, Preethi, et al.
Publicado: (2018)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Extinction of Zika Virus and Usutu Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic Drugs
por: Bassi, Maria Rosaria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gth6asm3midek6j4e84khulu9s